You don’t hold you have no sentiment . Do you realise that this stock is on the cusp of something very special . I have been involved in the market for thirty years and seen all sorts of charts double tops saucer and handle triple watches you can run an argument for anything .inhave also held this stock for a very long time from the outset .
The facts are that this company has several ground breaking trials in the pipeline and have been successful on the first stage of It’s first trial , the ARDS trial .It is an excellent start and potentially globally significant . It also has massively increased its sales .
Regardless of whether it retraces to close the gap which as andres has espoused it is not assured as you must look at all gaps in the context of their significance and the facts are some gaps do not fill .The fundamentals are such that the SP will go higher IMO in the short term and re rate as they progress their trials , so forget the short term analysis look at the big picture and fundamentals .
The Bod and the medical experts are excellent . Many people print and comments on charts and T/A and profess to know charts and draw lines . The charts are historical and it is very difficult to predict short term moves , all one can say is that the stock is trending up or down and in this stock it is trending up based on the short term MA and long term MA .
As we know stocks do not run up or down in a straight line and fibonacci principles apply so the SP will see saw as all stocks do on Its way up , however , as long as the fundamentals roll out as we expect they will , this stock will significantly rerate in time and all the analysis of historical data short term will not mean squat if they deliver what they set out in their strategy .
BTW in any event stocks that set double top footprints with solid newsflow and excellent fundamentals recover from them regardless of any short term double top they have printed . So IMO there are no absolutes and generalised references to charts and other stocks and their charts do not apply . If IHL deliver positive news on any one of these trials ( and it has a stage 1 ards success already ) they will be rerated to $200-$300 m MC on any one of them being successful IMO . They are an IP / Big Pharma business and we need to allow them time to deliver . Patience is required here . It is not an easy task to build a Big Pharma business .
I have confidence that we will see this stock in the 20s in the short term as it progresses its strategy based on the newsflow we know is coming IMO .
IHL Price at posting:
7.0¢ Sentiment: Buy Disclosure: Held
